JP2024523290A - がんの処置およびその方法における使用のための、マスクされたI型インターフェロン(IFNαおよびIFNβ)を含む融合タンパク質組成物 - Google Patents

がんの処置およびその方法における使用のための、マスクされたI型インターフェロン(IFNαおよびIFNβ)を含む融合タンパク質組成物 Download PDF

Info

Publication number
JP2024523290A
JP2024523290A JP2023577156A JP2023577156A JP2024523290A JP 2024523290 A JP2024523290 A JP 2024523290A JP 2023577156 A JP2023577156 A JP 2023577156A JP 2023577156 A JP2023577156 A JP 2023577156A JP 2024523290 A JP2024523290 A JP 2024523290A
Authority
JP
Japan
Prior art keywords
ifn
antibody
masked
interferon
mask
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023577156A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024523290A5 (cg-RX-API-DMAC7.html
Inventor
デイビッド ストーバー,
シェリー モリソン,
アレックス ヴァスタサワット,
カム トリン,
Original Assignee
ナミ セラピューティクス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナミ セラピューティクス, インコーポレイテッド filed Critical ナミ セラピューティクス, インコーポレイテッド
Publication of JP2024523290A publication Critical patent/JP2024523290A/ja
Publication of JP2024523290A5 publication Critical patent/JP2024523290A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023577156A 2021-06-18 2022-06-17 がんの処置およびその方法における使用のための、マスクされたI型インターフェロン(IFNαおよびIFNβ)を含む融合タンパク質組成物 Pending JP2024523290A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163259105P 2021-06-18 2021-06-18
US63/259,105 2021-06-18
PCT/US2022/000011 WO2022265679A2 (en) 2021-06-18 2022-06-17 FUSION PROTEIN COMPOSITION(S) COMPRISING MASKED TYPE I INTERFERONS (IFNα AND IFNβ) FOR USE IN THE TREATMENT OF CANCER AND METHODS THEREOF

Publications (2)

Publication Number Publication Date
JP2024523290A true JP2024523290A (ja) 2024-06-28
JP2024523290A5 JP2024523290A5 (cg-RX-API-DMAC7.html) 2025-06-24

Family

ID=82786512

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023577156A Pending JP2024523290A (ja) 2021-06-18 2022-06-17 がんの処置およびその方法における使用のための、マスクされたI型インターフェロン(IFNαおよびIFNβ)を含む融合タンパク質組成物

Country Status (9)

Country Link
US (2) US20250325634A1 (cg-RX-API-DMAC7.html)
EP (1) EP4329794A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024523290A (cg-RX-API-DMAC7.html)
KR (1) KR20240021943A (cg-RX-API-DMAC7.html)
CN (1) CN117529330A (cg-RX-API-DMAC7.html)
AU (1) AU2022292462A1 (cg-RX-API-DMAC7.html)
CA (1) CA3221878A1 (cg-RX-API-DMAC7.html)
IL (1) IL308959A (cg-RX-API-DMAC7.html)
WO (1) WO2022265679A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4750813A1 (en) * 2023-07-25 2026-06-03 TJ Biopharma (Shanghai) Co., Ltd. Masked interferon fusion proteins and uses thereof
WO2026117686A1 (en) * 2024-11-27 2026-06-04 Nammi Therapeutics, Inc. FUSION PROTEIN COMPOSITION(S) COMPRISING MASKED TYPE I INTERFERONS (IFNα AND IFNβ) FOR USE IN THE TREATMENT OF CANCER AND METHODS THEREOF

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012520059A (ja) * 2009-02-23 2012-09-06 サイトムエックス セラピューティクス, インコーポレイテッド プロタンパク質およびその使用方法
JP2013541937A (ja) * 2010-08-05 2013-11-21 エフ.ホフマン−ラ ロシュ アーゲー 抗mhc抗体−抗ウイルス性サイトカイン融合タンパク質
JP2015500796A (ja) * 2011-10-28 2015-01-08 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド ポリペプチド構築物およびその使用
WO2020160182A1 (en) * 2019-01-30 2020-08-06 The Regents Of The University Of California Targeted delivery of ifn gamma using antibody fusion proteins
JP2020528878A (ja) * 2017-06-20 2020-10-01 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム がん治療用インターフェロンプロドラッグ
WO2020214690A1 (en) * 2019-04-15 2020-10-22 Qwixel Therapeutics Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
KR100845354B1 (ko) 2004-03-26 2008-07-09 화이자 프로덕츠 인코포레이티드 항-ctla-4 항체의 용도
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
US9803021B2 (en) 2012-12-07 2017-10-31 The Regents Of The University Of California CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012520059A (ja) * 2009-02-23 2012-09-06 サイトムエックス セラピューティクス, インコーポレイテッド プロタンパク質およびその使用方法
JP2013541937A (ja) * 2010-08-05 2013-11-21 エフ.ホフマン−ラ ロシュ アーゲー 抗mhc抗体−抗ウイルス性サイトカイン融合タンパク質
JP2015500796A (ja) * 2011-10-28 2015-01-08 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド ポリペプチド構築物およびその使用
JP2020528878A (ja) * 2017-06-20 2020-10-01 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム がん治療用インターフェロンプロドラッグ
WO2020160182A1 (en) * 2019-01-30 2020-08-06 The Regents Of The University Of California Targeted delivery of ifn gamma using antibody fusion proteins
WO2020214690A1 (en) * 2019-04-15 2020-10-22 Qwixel Therapeutics Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CELL, vol. 146, JPN6026018118, 2011, pages 621 - 632, ISSN: 0005852972 *
PNAS, vol. 98, no. 23, JPN6026018119, 2001, pages 13231 - 13236, ISSN: 0005852973 *

Also Published As

Publication number Publication date
US20260146101A1 (en) 2026-05-28
AU2022292462A1 (en) 2023-12-07
WO2022265679A9 (en) 2023-05-19
IL308959A (en) 2024-01-01
WO2022265679A2 (en) 2022-12-22
WO2022265679A3 (en) 2023-01-26
EP4329794A2 (en) 2024-03-06
CN117529330A (zh) 2024-02-06
CA3221878A1 (en) 2022-12-22
KR20240021943A (ko) 2024-02-19
US20250325634A1 (en) 2025-10-23

Similar Documents

Publication Publication Date Title
US12162958B2 (en) Fusion protein composition(s) comprising masked type i interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof
US9777071B2 (en) Anti-DPEP3 antibodies and methods of use
US20170073430A1 (en) Novel anti-rnf43 antibodies and methods of use
JP2019500335A (ja) 新規の抗クローディン抗体及び使用方法
JP2016536020A (ja) 新規の抗クローディン抗体および使用方法
JP2019506136A (ja) 新規抗emr2抗体及び使用方法
WO2022159984A1 (en) Anti-her-2/trop-2 constructs and uses thereof
US20180312561A1 (en) Focused interferon immunotherapy for treatment of cancer
US20240279342A1 (en) Compositions and methods for immunotherapy
JP2025504738A (ja) クローディン18.2アンタゴニストおよびpd-1/pd-l1系阻害剤の併用療法
US20190016812A1 (en) Novel anti-tnfsf9 antibodies and methods of use
US20250325634A1 (en) Fusion Protein Composition(s) Comprising Masked Type I Interferons (IFNa and IFNb) For Use in the Treatment of Cancer and Methods Thereof
JP2019525727A (ja) 新規の抗tnfrsf21抗体及び使用方法
AU2020353217A1 (en) Treatment involving therapeutic antibody and interleukin-2 (IL2)
US12539340B2 (en) Radioconjugates targeting CD33 in the treatment of cancers
WO2017180764A1 (en) Focused interferon immunotherapy
WO2025264533A1 (en) Methods and compositions related to antibody drug conjugates (adcs) that bind steap-1 proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250616

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260807